Susquehanna International Group, LLP Editas Medicine, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$4.67 - $7.28 $965,756 - $1.51 Million	-206,800 Reduced 74.66%	70,200 $327,000
Q1 2024 May 07, 2024	SELL	$7.03 - $11.07 $856,254 - $1.35 Million	-121,800 Reduced 30.54%	277,000 $2.06 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $1.72 Million - $3.05 Million	274,700 Added 221.35%	398,800 $4.04 Million
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $69,200 - $93,100	-10,000 Reduced 7.46%	124,100 $967,000
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $344,076 - $620,527	54,100 Added 67.63%	134,100 $1.1 Million
Q1 2023 May 16, 2023	SELL	$7.03 - $11.53 $1.15 Million - $1.89 Million	-164,000 Reduced 67.21%	80,000 $580,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $430,976 - $684,278	51,800 Added 26.95%	244,000 $2.16 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.49 Million - $2.38 Million	122,700 Added 176.55%	192,200 $2.35 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $66,933 - $143,045	6,700 Added 10.67%	69,500 $822,000
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $446,336 - $875,871	-31,700 Reduced 33.54%	62,800 $1.19 Million
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $9.44 Million - $14.4 Million	-355,600 Reduced 79.0%	94,500 $2.51 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $3.46 Million - $6.43 Million	88,200 Added 24.37%	450,100 $18.5 Million
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $103,257 - $186,912	3,300 Added 0.92%	361,900 $20.5 Million
Q1 2021 May 17, 2021	SELL	$39.71 - $90.58 $5.73 Million - $13.1 Million	-144,200 Reduced 28.68%	358,600 $15.1 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $10.1 Million - $31.5 Million	373,000 Added 287.37%	502,800 $35.3 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $230,092 - $304,712	8,200 Added 6.74%	129,800 $3.64 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1.25 Million - $2.32 Million	67,600 Added 125.19%	121,600 $3.6 Million
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $168,144 - $370,414	11,300 Added 26.46%	54,000 $1.07 Million
Q4 2019 Feb 14, 2020	SELL	$19.49 - $32.63 $1.03 Million - $1.72 Million	-52,800 Reduced 55.29%	42,700 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $155,181 - $184,989	6,900 Added 7.79%	95,500 $2.17 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $296,960 - $402,520	-14,500 Reduced 14.06%	88,600 $2.19 Million
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $369,170 - $501,790	19,000 Added 22.59%	103,100 $2.52 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $1.61 Million - $2.81 Million	-88,300 Reduced 51.22%	84,100 $1.91 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $3.39 Million - $4.71 Million	-122,600 Reduced 41.56%	172,400 $5.49 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $2.4 Million - $3.13 Million	-76,400 Reduced 20.57%	295,000 $10.6 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $3.81 Million - $5.63 Million	127,800 Added 52.46%	371,400 $12.3 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $1.45 Million - $2.07 Million	66,200 Added 37.32%	243,600 $7.49 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $2.8 Million - $4.26 Million	177,400	177,400 $4.26 Million

Others Institutions Holding EDIT

# of Institutions

252

Shares Held

58.7M

Call Options Held

494K

Put Options Held

417K

Vanguard Group Inc Valley Forge, PA

8.03M
Shares

$26.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

7.78M
Shares

$25.4 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

6M
Shares

$19.6 Million
0.92% of portfolio
State Street Corp Boston, MA

4.59M
Shares

$15 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.46M
Shares

$8.04 Million
0.01% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $225M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account